Published in BMC Cancer on September 13, 2007
Preliminary results of a phase II trial of proton radiotherapy for pediatric rhabdomyosarcoma. J Clin Oncol (2014) 1.63
Effect of radiotherapy techniques (IMRT vs. 3D-CRT) on outcome in patients with intermediate-risk rhabdomyosarcoma enrolled in COG D9803--a report from the Children's Oncology Group. Int J Radiat Oncol Biol Phys (2011) 0.92
Intensity modulated radiotherapy (IMRT) in the treatment of children and adolescents--a single institution's experience and a review of the literature. Radiat Oncol (2009) 0.87
Rhabdomyosarcoma: a rare laryngeal neoplastic entity. Acta Otorhinolaryngol Ital (2010) 0.83
Perioperative intensity-modulated brachytherapy for refractory orbital rhabdomyosarcomas in children. Strahlenther Onkol (2009) 0.82
Ten years of progress in radiation oncology. BMC Cancer (2011) 0.82
Custom-designed mouthpiece for HDR brachytherapy of embryonal rhabdomyosarcoma of the soft palate. J Contemp Brachytherapy (2014) 0.78
Late Toxicities of Intensity-Modulated Radiation Therapy for Head and Neck Rhabdomyosarcoma. Pediatr Blood Cancer (2016) 0.75
Head and neck sarcoma: report of a case treated by intensity-modulated radiation therapy. Int J Clin Oncol (2010) 0.75
Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol (2001) 5.46
The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol (1995) 5.36
Survival analysis part I: basic concepts and first analyses. Br J Cancer (2003) 4.08
Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol (2004) 3.56
Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol (1995) 3.00
Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG. Int J Radiat Oncol Biol Phys (2001) 2.44
Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol (1999) 2.25
Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol (2001) 2.06
Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors. CA Cancer J Clin (2004) 2.05
Intensity-modulated radiotherapy for head-and-neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys (2005) 1.82
Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Children's Cancer Study Group. Pediatric Oncology Group. Cancer (1997) 1.67
Parameningeal rhabdomyosarcoma: results of an international workshop. Int J Radiat Oncol Biol Phys (1996) 1.50
Proton radiotherapy for orbital rhabdomyosarcoma: clinical outcome and a dosimetric comparison with photons. Int J Radiat Oncol Biol Phys (2005) 1.28
Long-term effects in children treated with radiotherapy for head and neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys (2000) 1.27
Optimized planning using physical objectives and constraints. Semin Radiat Oncol (1999) 1.20
Precision radiotherapy for hemangiopericytomas of the central nervous system. Cancer (2005) 1.12
Late effects of radiotherapy for pediatric extremity sarcomas. Int J Radiat Oncol Biol Phys (2004) 1.10
Stereotactic intensity modulated radiation therapy and inverse treatment planning for tumors of the head and neck region: clinical implementation of the step and shoot approach and first clinical results. Radiother Oncol (2003) 1.05
Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II). J Clin Oncol (1987) 1.04
Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease. Strahlenther Onkol (2006) 1.03
Orbital rhabdomyosarcoma. Cancer Control (2004) 1.00
Factors leading to delay in the diagnosis and affecting survival of children with head and neck rhabdomyosarcoma. Pediatrics (1978) 0.94
Head and neck rhabdomyosarcoma. Semin Pediatr Surg (1994) 0.91
Esthesioneuroblastoma in childhood and adolescence. Better prognosis with multimodal treatment? Strahlenther Onkol (2005) 0.91
Group II rhabdomyosarcoma and rhabdomyosarcomalike tumors: is radiotherapy necessary? J Clin Oncol (2004) 0.90
Radiobiological investigation of dose-rate effects in intensity-modulated radiation therapy. Strahlenther Onkol (2005) 0.87
[Inverse radiotherapy planning for intensity modulated photon fields]. Radiologe (1998) 0.87
Photogrammetric accuracy measurements of head holder systems used for fractionated radiotherapy. Int J Radiat Oncol Biol Phys (1994) 0.86
A novel local treatment strategy for advanced stage head and neck rhabdomyosarcomas in children: results of the AMORE protocol. Eur J Cancer (2003) 0.85
Computer systems and mechanical tools for stereotactically guided conformation therapy with linear accelerators. Int J Radiat Oncol Biol Phys (1992) 0.83
Achievement of long-term local control in patients with craniopharyngiomas using high precision stereotactic radiotherapy. Cancer (2007) 0.83
Rhabdomyosarcoma of Parameningeal Sites. Semin Radiat Oncol (1997) 0.82
Local control of parameningeal rhabdomyosarcoma: outcomes in non-complete responders to chemoradiation. Med Pediatr Oncol (2003) 0.81
Rhabdomyosarcoma of head and neck--an analysis of 24 cases. Indian J Cancer (1996) 0.81
Embryonal rhabdomyosarcoma of head and neck in children. Correlation of stage, radiation dose, local control, and survival. Cancer (1976) 0.80
Fractionated stereotactic conformal radiation therapy of brain stem gliomas: outcome and prognostic factors. Radiother Oncol (2000) 0.80
Measurements of characteristics of time pattern in dose delivery in step-and-shoot IMRT. Strahlenther Onkol (2005) 0.79
Intensive induction chemotherapy and delayed irradiation in the management of parameningeal rhabdomyosarcoma. J Pediatr Hematol Oncol (2003) 0.78
Head and neck rhabdomyosarcomas in children: value of clinical and CT findings in the detection of loco-regional relapses. Clin Radiol (1994) 0.77
Embryonal rhabdomyosarcoma of the head and neck in children. Laryngoscope (1973) 0.77
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 10.99
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell (2012) 6.07
Nonsense-mediated decay approaches the clinic. Nat Genet (2004) 5.12
Colorectal cancer. Lancet (2005) 4.90
Dissecting the genomic complexity underlying medulloblastoma. Nature (2012) 4.77
A sensitive array for microRNA expression profiling (miChip) based on locked nucleic acids (LNA). RNA (2006) 3.71
Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging (2013) 3.61
The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging (2014) 3.40
FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J Clin Oncol (2011) 3.33
Y14 and hUpf3b form an NMD-activating complex. Mol Cell (2003) 3.17
Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell (2011) 3.11
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med (2010) 2.97
Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell (2013) 2.89
Exon-junction complex components specify distinct routes of nonsense-mediated mRNA decay with differential cofactor requirements. Mol Cell (2005) 2.79
3' end mRNA processing: molecular mechanisms and implications for health and disease. EMBO J (2008) 2.67
Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med (2011) 2.59
Interactions between UPF1, eRFs, PABP and the exon junction complex suggest an integrated model for mammalian NMD pathways. EMBO J (2008) 2.52
Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine. Int J Radiat Oncol Biol Phys (2006) 2.48
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet (2013) 2.42
Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol (2010) 2.27
Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med (2005) 2.25
Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood (2006) 2.10
NMD: RNA biology meets human genetic medicine. Biochem J (2010) 2.09
Adult medulloblastoma comprises three major molecular variants. J Clin Oncol (2011) 2.07
Endostatin's antiangiogenic signaling network. Mol Cell (2004) 1.95
Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol (2011) 1.90
Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res (2009) 1.90
Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol (2012) 1.90
Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg (2007) 1.85
Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci U S A (2007) 1.85
TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol (2010) 1.83
Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. Acta Neuropathol (2010) 1.82
Complexes between the nonsense-mediated mRNA decay pathway factor human upf1 (up-frameshift protein 1) and essential nonsense-mediated mRNA decay factors in HeLa cells. Biochem J (2003) 1.74
Pancreatic cancer microenvironment. Int J Cancer (2007) 1.73
Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J Clin Invest (2007) 1.73
Disassembly of exon junction complexes by PYM. Cell (2009) 1.69
Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol (2010) 1.65
Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res (2005) 1.64
Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res (2005) 1.62
Improvement of surgical results for pancreatic cancer. Lancet Oncol (2013) 1.60
Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol (2005) 1.60
Nonsense-mediated mRNA decay: from vacuum cleaner to Swiss army knife. Genome Biol (2004) 1.59
Integration of splicing, transport and translation to achieve mRNA quality control by the nonsense-mediated decay pathway. Genome Biol (2002) 1.58
Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas. Int J Radiat Oncol Biol Phys (2007) 1.56
Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens. Int J Radiat Oncol Biol Phys (2008) 1.55
SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res (2003) 1.53
The abundance of RNPS1, a protein component of the exon junction complex, can determine the variability in efficiency of the Nonsense Mediated Decay pathway. Nucleic Acids Res (2007) 1.53
Intracellular visualization of prostate cancer using magnetic resonance imaging. Cancer Res (2003) 1.52
Using the lambdaN peptide to tether proteins to RNAs. Methods Mol Biol (2004) 1.52
Results of carbon ion radiotherapy in 152 patients. Int J Radiat Oncol Biol Phys (2004) 1.51
Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy. Int J Radiat Oncol Biol Phys (2004) 1.50
Multidisciplinary pain management based on a computerized clinical decision support system in cancer pain patients. Pain (2009) 1.48
The efficiency of nonsense-mediated mRNA decay is an inherent character and varies among different cells. Eur J Hum Genet (2007) 1.48
Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM). Cancer (2005) 1.46
Functions of hUpf3a and hUpf3b in nonsense-mediated mRNA decay and translation. RNA (2006) 1.46
Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol (2010) 1.46
A new concept for interactive radiotherapy planning with multicriteria optimization: first clinical evaluation. Radiother Oncol (2007) 1.45
Abnormally spliced beta-globin mRNAs: a single point mutation generates transcripts sensitive and insensitive to nonsense-mediated mRNA decay. Blood (2002) 1.43
Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging (2014) 1.43
Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res (2011) 1.42
Analysis of intrathoracic tumor mobility during whole breathing cycle by dynamic MRI. Int J Radiat Oncol Biol Phys (2004) 1.41
External beam radiotherapy in the treatment of male breast carcinoma: patterns of failure in a single institute experience. Tumori (2005) 1.40
4D-CT-based target volume definition in stereotactic radiotherapy of lung tumours: comparison with a conventional technique using individual margins. Radiother Oncol (2009) 1.39
MicroRNA expression after ionizing radiation in human endothelial cells. Radiat Oncol (2010) 1.38
Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. BMC Cancer (2010) 1.38
Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res (2008) 1.36
Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res (2003) 1.35
Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol (2015) 1.35
Analysis of gene expression profiles of microdissected cell populations indicates that testicular carcinoma in situ is an arrested gonocyte. Cancer Res (2009) 1.35
Carbon ion radiotherapy of skull base chondrosarcomas. Int J Radiat Oncol Biol Phys (2006) 1.33
Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. Acta Neuropathol (2011) 1.32
Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Radiat Oncol (2012) 1.28
Splicing factors stimulate polyadenylation via USEs at non-canonical 3' end formation signals. EMBO J (2007) 1.27
Assessment of focal liver reaction by multiphasic CT after stereotactic single-dose radiotherapy of liver tumors. Int J Radiat Oncol Biol Phys (2003) 1.27
Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med (2005) 1.25
Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials (2009) 1.24
The hierarchy of exon-junction complex assembly by the spliceosome explains key features of mammalian nonsense-mediated mRNA decay. PLoS Biol (2009) 1.24
Outcome and late complications of radiotherapy in patients with unicentric Castleman disease. Acta Oncol (2006) 1.24
Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma. Onkologie (2006) 1.24
NMD: multitasking between mRNA surveillance and modulation of gene expression. Adv Genet (2008) 1.23
Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival. Ann Surg Oncol (2012) 1.21
Fractionated stereotactic radiotherapy in patients with benign or atypical intracranial meningioma: long-term experience and prognostic factors. Int J Radiat Oncol Biol Phys (2005) 1.20
LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-β and BMP-associated proinflammatory and proangiogenic signals. Clin Cancer Res (2012) 1.20
Mechanism of escape from nonsense-mediated mRNA decay of human beta-globin transcripts with nonsense mutations in the first exon. RNA (2011) 1.19
The human intronless melanocortin 4-receptor gene is NMD insensitive. Hum Mol Genet (2002) 1.19
Hypofractionated carbon ion therapy delivered with scanned ion beams for patients with hepatocellular carcinoma - feasibility and clinical response. Radiat Oncol (2013) 1.19
Particle therapy at the Heidelberg Ion Therapy Center (HIT) - Integrated research-driven university-hospital-based radiation oncology service in Heidelberg, Germany. Radiother Oncol (2010) 1.18
Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys (2007) 1.18
A biological transporter for the delivery of peptide nucleic acids (PNAs) to the nuclear compartment of living cells. J Mol Biol (2002) 1.18
Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines. Int J Radiat Biol (2009) 1.17
Treatment of brain metastases from non-small-cell lung cancer (NSCLC): radiotherapy. Lung Cancer (2004) 1.17
Radiotherapeutic alternatives for previously irradiated recurrent gliomas. BMC Cancer (2007) 1.15